NCT04920227

Brief Summary

To compare the effect of intraocular pressure control and the incidence of peripheral anterior synechia between CLASS combined with phacoemulsification and CLASS alone in the treatment of primary open-angle glaucoma

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 2, 2020

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 1, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 9, 2021

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

June 9, 2021

Status Verified

August 1, 2020

Enrollment Period

2.9 years

First QC Date

June 1, 2021

Last Update Submit

June 4, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Incidence of peripheral anterior synechia

    Incidence of peripheral anterior synechia

    1 year

  • Intraocular pressure

    Intraocular pressure

    1 year

Study Arms (2)

CLASS+PHACO

EXPERIMENTAL

CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification

Procedure: phacoemulsification;

CLASS

NO INTERVENTION

CO2 Laser-Assisted Sclerectomy Surgery

Interventions

Group A: class combined with phacoemulsification

CLASS+PHACO

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Primary open-angle glaucoma patients with cataract in our Ophthalmic Center;
  • Topical use of hypotensive drugs in the treatment of poor or intolerable intraocular pressure control;
  • The patients were aged from 50 to 80 years old, regardless of gender;
  • Class operation and phacoemulsification were performed;
  • Patients are able and willing to comply with the research guidance and may complete all visits required by the research;
  • Informed consent has been signed.

You may not qualify if:

  • Allergic to any perioperative medication in this study;
  • History of ocular trauma;
  • Any previous intraocular surgery;
  • Angle of the chamber was narrow by angle microscopy (Schaffer grade III and below);
  • Patients diagnosed as secondary glaucoma;
  • Optic atrophy caused by other reasons;
  • The serious complications such as posterior capsule rupture and choroidal hemorrhage occurred during the operation;
  • Serious complications of eyes occurred after operation;
  • The patient's history indicated that he had severe dysfunction of heart, lung, liver and kidney;
  • Women in pregnancy, lactation or planned pregnancy;
  • The researchers believe that the patient's condition may put the patient at significant risk, and may confuse the research results.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eye Center, the 2nd Affiliated Hospital, Medical College of Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-Angle

Interventions

Phacoemulsification

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye Diseases

Intervention Hierarchy (Ancestors)

Cataract ExtractionRefractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, OperativeUltrasonic Surgical Procedures

Study Officials

  • Kaijun Wang, MD

    Eye Center, the 2nd Affiliated Hospital, Medical College of Zhejiang University

    STUDY DIRECTOR

Central Study Contacts

Kaijun Wang, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2021

First Posted

June 9, 2021

Study Start

September 2, 2020

Primary Completion

August 1, 2023

Study Completion

August 1, 2023

Last Updated

June 9, 2021

Record last verified: 2020-08

Locations